


Supplementary Figure 1. Serum cytokine levels in patients with HNSCC and controls. **A**, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). **B**, Comparison of serum TGF- β 1 levels in non-cancer controls and patients with HNSCC at the time of new diagnosis and at the time of recurrence. **C**, Comparison of serum levels of TGF- β 1 in patients with HPV-negative HNSCC at the time of diagnosis, and at two time points after the completion of treatment.



Supplementary Table 1**Clinical characteristics of patients with HNSCC**

	New Diagnosis (N=36)	Recurrence (N=11)
Sex		
Male	24	10
Female	12	1
Subsites		
Oral Cavity	11	3
Oropharynx	22	1
Larynx	3	4
Hypopharynx	0	3
T Stage		
T1/T2	29	6
T3/T4	7	5
N Stage		
N0	6	8
N ⁺	30	3
HPV		
Positive	18	0
Negative	18	11

Supplementary Table 2. Tumor HPV status and serum TGF- β 1 levels of HNSCC patients.

Plasma ID	HPV Status	TGF- β 1 level
836	+	15400
1282	-	20000
1406	+	137
1561	-	19000
2208	-	19400
2613	-	25000
2712	-	44900
2745	+	10702
2774	+	24500
2775	-	10500
3808	-	15600
3827	+	28200
3959	-	17800
3966	-	37900
4227	+	11600
4384	+	7100
4785	+	8790
5023	-	2530
5333	-	2100
7853	+	5270
8997	+	3990
9309	+	5210
13207	-	24900
13300	-	24300
14982	-	10700
15220	-	9040
15247	+	11700
18419	-	21929
21539	-	32600
22475	-	30000
22485	-	27400
23909	+	28800
25798	-	20100
26425	-	28500
29338	-	28000
30514	-	36400
30535	+	45100
30613	-	32600
30764	+	61.7
30848	-	25600
31140	-	33600
31246	+	38900
31353	-	16800
31632	-	30000
32843	-	46200
3944_1P	+	17900
3957_1P	-	20400
4020_1P	+	30300
4036_1P	-	26234